Veterans Affairs Medical Center - Kansas City

Summary

Veterans Affairs Medical Center - Kansas City is a medical facility located in Kansas City, Missouri. This center is recognized for care of Lung Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer, Leukemia and other specialties. Veterans Affairs Medical Center - Kansas City is involved with conducting 247 clinical trials across 408 conditions. There are 11 research doctors associated with this hospital, such as Chao H. Huang, Suman Kambhampati, Prateek Sharma, MD, and Ajay Bansal.

Top PIs

Clinical Trials running at Veterans Affairs Medical Center - Kansas City

Prostate Cancer

Bladder Cancer

Lung Cancer

Lymphoma

Pancreatic Cancer

Heart Failure

Multiple Myeloma

Colorectal Cancer

Cancer

Atherosclerosis

High Dose Testosterone

for Prostate Cancer

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis

Recruiting

3 awards

Phase 2

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Carboplatin vs Olaparib

for Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.

Recruiting

1 award

Phase 2